Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BeiGene Ltd ( (HK:6160) ) just unveiled an update.
BeOne Medicines Ltd. has announced that its audit committee will review and approve the interim results for the six months ended June 30, 2025, on August 28, 2025. These results, previously announced and filed with the SEC, will be published in accordance with the Hong Kong Listing Rules, including additional information and a reconciliation from U.S. GAAP to IFRS.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$156.80 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
More about BeiGene Ltd
Average Trading Volume: 6,509,881
Technical Sentiment Signal: Buy
Current Market Cap: HK$293B
See more insights into 6160 stock on TipRanks’ Stock Analysis page.